Search clinical trials for: intermediate risk

Total 16000 results

Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia
Hospices Civils de Lyon

Unknown

Medical and Economic Evaluation for Intermediate-risk Prostate Cancer (GETUGP05)

Prostate Cancer

France
University of Zurich

Terminated

High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Trial Comparing MitraClip® to Surgical Therapy (HiRiDe)

Mitral Valve Insufficiency

Germany, Italy, Switzerland
Tarix Pharmaceuticals

Terminated

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

Myelodysplastic Syndrome (MDS)

United States
Apogenix GmbH

Completed

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

Myelodysplastic Syndrome

Germany
Sophiris Bio Corp

Completed

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Prostate Cancer

United Kingdom
CureVac

Terminated

An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer

Prostate Carcinoma

Germany
Roswell Park Cancer Institute
Genzyme, a Sanofi Company

Terminated

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Myelodysplastic Syndrome

United States
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Incretin-based Drugs and the Risk of Heart Failure

Type 2 Diabetes Mellitus

Canada
Albert DeNittis

Unknown

Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer

Prostate Neoplasms

United States
Fox Chase Cancer Center
Genentech, Inc.

Withdrawn

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Chiang Mai University

Completed

The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.

ST-elevation Myocardial Infarction

Thailand
Asociación Andaluza de Hematología y Hemoterapia

Completed

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia (ABRAZA)

Myelodysplastic Syndrome (MDS)

Spain
Sanofi

Completed

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

Hematopoietic Neoplasm

Austria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
Assistance Publique Hopitaux De Marseille

Unknown

Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (GIGIST)

Gastrointestinal Stromal Tumor
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Withdrawn

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, B-Cell, Marginal Zone | Lymphoma, Low-Grade | Lymphoma, Intermediate-Grade
University of Waterloo
Grand River Regional Cancer Centre

Completed

Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer

Prostate Cancer

Canada
The Affiliated Hospital of the Chinese Academy...

Completed

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Acute Myeloid Leukemia

China
Groupe Francophone des Myelodysplasies
Celgene Corporation

Unknown

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (GFM-Chimio-Rev)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

France
Genzyme, a Sanofi Company

Terminated

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome (RISE)

Myelodysplastic Syndrome (MDS)

Germany, United Kingdom, France, Netherlands
Ginna Laport

Terminated

Haploid Allogeneic Transplant Using the CliniMACS System

Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors | Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase | Myelodysplastic Syndrome (MDS) - High and Intermediate Risk | Non-Hodgkin's Lymphoma (NHL) | Chronic Lymphocytic Leukemia...

United States
Technical University of Munich

Completed

Correlation Between Reticulated Platelets and Major Adverse Cardiac and Cerebrovascular Events After Noncardiac Surgery

Stroke | Angina Pectoris | Deep Vein Thrombosis | Pulmonary Embolism | Congestive Heart Failure | Cardiac Death

Germany
Southern California Institute for Research and...

Unknown

Role of Heme-oxygenase (HO) and Nitric Oxide (NO) Pathway in Patients With Obstructive Sleep Apnea (OSA) and Pulmonary Hypertension (PH)

Obstructive Sleep Apnea | Pulmonary Hypertension
Prince of Songkla University

Completed

The Cost Effectiveness of Endoscopic Ultrasound ( EUS ) Based Strategy in Diagnosis of Common Bile Duct Stones

Common Bile Duct Calculi

Thailand
Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Completed

Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Hospital de Cruces

Unknown

Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer (SINFRA_PROST)

Prostate Cancer

Spain
Eisai Inc.

Terminated

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Myelodysplastic Syndromes

United States
Janssen Research & Development, LLC

Terminated

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Prof. Paolo Bruzzi

Unknown

Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk (MRIB)

Breast Cancer

Italy
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Vancouver Coastal Health
Lotte & John Hecht Memorial Foundation

Terminated

Study of POMELLA™ Extract to Treat Prostate Cancer

Prostate Cancer

Canada
Riverside Community Hospital, California

Unknown

CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Rocky Mountain Cancer Centers
Dr. Dennis Carter

Withdrawn

Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer (Prostate SBRT)

Prostate Cancer

United States
Nutrasource Pharmaceutical and Nutraceutical Services...
University of Guelph; Biodroga Inc.

Completed

Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy

Cardiovascular Disease

Canada
The Vaccine Company

Unknown

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Telik

Terminated

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Eisai Inc.

Completed

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo
Royal Marsden NHS Foundation Trust

Completed

Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum

Rectum Cancer

Spain
Celgene Corporation

Completed

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
St. Jude Children's Research Hospital

Withdrawn

Markers of Anthracycline-Related Cardiac Muscle Injury

Osteosarcoma | Rhabdomyosarcoma | Ewing's Sarcoma Family of Tumors | Non-rhabdomyosarcoma Soft Tissue Sarcomas
Telik

Completed

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Trans Tasman Radiation Oncology Group

Completed

Assessment of New Radiation Oncology Technologies and Treatments (ANROTAT)

Nasopharyngeal Cancer | Anal Cancer | Intermediate Risk Prostate Cancer | Prostate Cancer (Post Prostatectomy)

Australia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia (AML-14A)

Myelodysplastic Syndromes | Leukemia

Belgium, Croatia, France, Italy, Netherlands
University of California, San Francisco

Withdrawn

Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers

Cardiac Event Risk

United States
Seoul National University Hospital
Samsung Medical Center; Seoul St. Mary's Hospital; Asan Medical Center; Seoul National... and other collaborators

Unknown

Comparison of the Cost-Effectiveness of Coronary CT Angiography Versus Myocardial SPECT in Patients With Intermediate Risk of Coronary Heart Disease (CARE-CCTA)

Chest Pain | Coronary Heart Disease Risk

Korea, Republic of
John Chang, MD

Unknown

An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer (Clarity)

Prostate Adenocarcinoma

United States

Search clinical trials for: intermediate risk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations